---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-273329"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:27:17.322586+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CRISPR Therapeutics Q3 net loss widens to $106M; CASGEVY momentum builds, CTX310 Phase 1 data positive

## Summary
- Q3 net loss $106.4M vs $85.9M YoY; cash & equivalents $1.94B (flat vs Dec 2024).
- CASGEVY: 165 patients completed cell collection, 39 infused; Vertex expects >$100M revenue in 2025.
- CTX310 Phase 1 data at AHA/NEJM show durable TG and LDL reduction; advancing to Phase 1b.
- CTX460 (SyNTase) preclinical data >90% mRNA correction in AATD; trial planned mid-2026.
- SRSD107 Phase 2 first patient dosed for thromboembolic disorders; trial expanded in Europe.

## SEC filing metadata
- accession: 0001193125-25-273329
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000119312525273329/0001193125-25-273329-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000119312525273329/crsp-20251110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-273329
- JSON: https://secwatch.observer/filing/0001193125-25-273329.json
- Plain text: https://secwatch.observer/filing/0001193125-25-273329.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.